HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights
ALDURAZYME® (laronidase) injection for intravenous use. Initial U.S. Approval: 2003 ALDURAZYME® is a registered trademark of BioMarin/Genzyme LLC.
aldurazyme
Laronidase (Aldurazyme) Biomarin Pharmaceutical Inc
Patients treated with ALDURAZYME may develop infusion-related hypersensitivity reactions (see ADVERSE REACTIONS). In the clinical studies one patient developed
larobio LB
BioMarin Pharmaceutical Inc.
26 févr. 2021 We developed Aldurazyme through collaboration with Sanofi Genzyme (Genzyme) now a wholly owned subsidiary of Sanofi. Under our.
BMRN (BioMarin Pharmaceutical Inc.) ( K)
Aldurazyme INN-laronidase
Aldurazyme is intended for the treatment of Mucopolysaccharidosis I (MPS I) of the formulated bulk active substance (rhIDU) takes place at BioMarin.
aldurazyme epar scientific discussion en
Aldurazyme® (laronidase) Product Monograph
8 août 2014 Aldurazyme. ® is a registered trademark of BioMarin/Genzyme LLC. Genzyme Canada a division of sanofi-aventis Canada Inc.
aldurazyme en
BioMarin Pharmaceutical Inc.
27 févr. 2020 We developed Aldurazyme through collaboration with Genzyme Corporation (Genzyme) now a wholly owned subsidiary of Sanofi. Under our.
BMRN (BioMarin Pharmaceutical Inc.) ( K)
Test Category: Adverse Event Hypersensitivity
Aldurazyme is a registered trademark of BioMarin/Genzyme LLC. Sanofi Rare Disease. Specialty Testing Program. Royal Children's Hospital. 4th Floor East
SR E Royal Children's Hospital Sanofi AE Hypersensitivity TRF
BioMarin Pharmaceutical Inc.
25 févr. 2022 BioMarin Brineura
BMRN (BioMarin Pharmaceutical Inc.) ( K)
ALDURAZYME - Sanofi Conecta
ALDURAZYME é indicado a pacientes com as formas Hurler e Hurler-Scheie da doença ALDURAZYME é uma marca registrada da BioMarin/Genzyme LLC.
MONOGRAPHIE DE PRODUIT
8 août 2014 Genzyme Canada a division of sanofi-aventis Canada Inc. Date de révision: ... Aldurazyme® est une marque déposée de BioMarin/Genzyme LLC.
aldurazyme fr